GRONINGEN, THE NETHERLANDS — The oral administration of cannabis extracts containing THC and CBD is associated with pain reduction in patients suffering from the skin disease epidermolysis bullosa (EB), according to three case reports published in The British Journal of Dermatology.
Epidermolysis bullosa is a rare genetic condition that results in blistering skin.
Dutch researchers assessed the use of cannabis extracts in three patients with EB. All three patients reported “improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.”
They concluded that the findings “warrant further investigations of CBMs (cannabis-based medicines) in controlled study settings in order to objectify the reported pain changes observed in these cases, and close the gap between current treatment standards and patient needs.”
Earlier this year, US investigators reported that the topical administration of CBD in three patients with EB was associated with a “reduction in pain and blistering,” “rapid wound healing,” and “the objective need for less analgesic [medicines].”
Full text of the study, “Combined THC and CBD to treat pain in epidermolysis bullosa: A report of three cases,” appears in The British Journal of Dermatology.